I've been reading about the potential of SGLT2 inhibitors to reduce autoimmune risks in diabetes care. I'm curious what others think we should focus on to effectively integrate these benefits. Feel free to share your thoughts by voting below!

What should be the primary focus to integrate the autoimmune benefits of SGLT2 inhibitors into diabetes care?